{"uid":"cap_0pJzRj0EJUaahXBkWP_I4","slug":"clinicalintelpulse-biotech-m-a-deal-signal-8aa4b5c3","name":"ClinicalIntelPulse Biotech M&A Deal Signal","description":"Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"stage":{"type":"string"},"condition":{"type":"string"},"deal_type":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"as_of":"2026-06-07","stage":"both","condition":"Obesity","deal_type":"both"},"market_context":{"approved_leaders":["Semaglutide (Novo Nordisk — Wegovy)","Tirzepatide (Lilly — Zepbound)"],"big_pharma_strategic_need":"Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.","total_addressable_market_usd_bn":100},"recent_deal_comps":[{"deal":"Roche / Carmot Therapeutics","year":2023,"stage":"PHASE1/2","mechanism":"GLP-1 peptide","value_usd_bn":2.7},{"deal":"AstraZeneca / Eccogene","year":2024,"stage":"PHASE2","mechanism":"Small-molecule GLP-1","value_usd_bn":1.85},{"deal":"Amgen / ChemoCentryx","year":2022,"stage":"Approved","mechanism":"C5aR1","value_usd_bn":3.7}],"acquisition_targets":[{"asset":"Mazdutide (IBI362)","risks":["China geopolitical risk for IP transfer","Phase 3 US/EU data needed before deal close"],"stage":"PHASE3","company":"Innovent Biologics (China)","deal_comp":"Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.","mechanism":"GLP-1/glucagon dual agonist","probability":"High","clinical_data":"Phase 3 China data strong — 14.5% body weight reduction at 52 weeks","deal_rationale":"Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.","estimated_deal_value_usd_m":"800-2000"}],"deal_timing_signals":"Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.","licensing_opportunities":[{"asset":"CT-388 (dual GLP-1/GIP)","notes":"Roche may sublicense ex-US rights to regional partners in Asia/LatAm","company":"Carmot Therapeutics (acq. Roche)","estimated_license_value_usd_m":"300-800"}]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.35","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.35/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_-lWuie16NMV8auoJcw2iC","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.35","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns M&A and licensing deal signals for clinical-stage Phase 2/3 drug assets — identifying acquisition targets, deal comparables, transaction multiples, and estimated deal values worldwide.","exampleAgentPrompt":"Which Phase 2 and Phase 3 oncology drug assets are showing the strongest M&A or licensing deal signals right now — give me the likely acquisition targets, recent deal comps, and estimated transaction multiples.","exampleUseCases":null,"resultDescription":"A structured list of clinical-stage (Phase 2/3) drug assets ranked by acquisition or licensing likelihood, with identified acquirer targets, comparable past transactions, deal multiples (e.g. revenue or pipeline multiples), and estimated deal values — scoped worldwide.","failureModes":["Unknown or unsupported disease area returns empty results or 404","Overly broad query with no disease/therapeutic filter may return low-confidence signals","Rate limiting or payment failure (402) if USDC payment not properly configured","No active Phase 2/3 assets in a niche indication returns empty deal signal list","Stale deal comp data if no recent transactions in the queried therapeutic area"],"whenToPreferThis":"Use this endpoint when you need actionable M&A and licensing intelligence specifically for clinical-stage biotech assets — particularly when an investor, BD team, or agent needs deal probability scoring, transaction comps, and estimated valuations for Phase 2/3 drugs. Prefer this over general pipeline endpoints when the goal is deal-making or investment targeting rather than scientific or trial-design analysis.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-13T12:34:22.813Z","isFirstParty":false}